Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T.

Nat Med. 2000 Aug;6(8):916-9.

PMID:
10932230
2.

Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D.

J Neurosci. 2003 May 1;23(9):3745-51.

3.

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE.

J Neurosci. 2003 Sep 17;23(24):8532-8.

4.

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P.

Nature. 1999 Jul 8;400(6740):173-7.

PMID:
10408445
5.

Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology.

Mehlhorn G, Hollborn M, Schliebs R.

Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):423-31.

PMID:
10817926
6.

Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations.

Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT.

J Neurosci. 2003 Nov 26;23(34):10879-83.

7.

Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE.

J Neurosci. 2006 Nov 15;26(46):11923-8. Erratum in: J Neurosci. 2006 Dec 6;26(49):preceding 12847.

8.

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. Epub 2001 Jul 3.

9.

Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ.

Ann Neurol. 2000 Oct;48(4):567-79.

PMID:
11026440
10.

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F.

Brain Pathol. 2004 Jan;14(1):11-20.

PMID:
14997933
11.

In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.

Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM.

J Neurochem. 2007 Jul;102(2):420-33.

12.

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease.

Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D, He W.

Neurobiol Dis. 2003 Dec;14(3):365-79.

PMID:
14678754
13.

beta-peptide immunization: a possible new treatment for Alzheimer disease.

Schenk DB, Seubert P, Lieberburg I, Wallace J.

Arch Neurol. 2000 Jul;57(7):934-6. Review. No abstract available.

PMID:
10891974
14.

Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.

Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ.

PLoS Med. 2007 Aug;4(8):e262.

15.

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.

Frenkel D, Dewachter I, Van Leuven F, Solomon B.

Vaccine. 2003 Mar 7;21(11-12):1060-5.

PMID:
12559780
16.

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE.

Neurobiol Aging. 2001 Sep-Oct;22(5):721-7.

PMID:
11705631
17.

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D.

Nature. 2000 Dec 21-28;408(6815):979-82.

PMID:
11140685
18.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
19.

Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging.

Nakagawa Y, Nakamura M, McIntosh TK, Rodriguez A, Berlin JA, Smith DH, Saatman KE, Raghupathi R, Clemens J, Saido TC, Schmidt ML, Lee VM, Trojanowski JQ.

J Comp Neurol. 1999 Aug 30;411(3):390-8.

PMID:
10413774
20.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076

Supplemental Content

Support Center